Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir Intensification in HIV-1 on PI Monotherapy
NCT01480713Phase 3Completed
- Sponsor
- IrsiCaixa
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by IrsiCaixa. Primary endpoints: Integrated viral HIV-1 DNA in PBMCs at 24 weeks, Unintegrated viral HIV-1 DNA in PBMCs at 24 weeks and 1 more. Started May 2012; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01480713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480713.